A Microsoft executive said the acquisition will allow for an advertising platform that doesn't rely on tracking technologies. Read More...
Motley Fool
Better Buy: Viatris vs. AbbVie
With a market cap of nearly $16 billion, the generic drugmaker Viatris (NASDAQ: VTRS) is minuscule in comparison to the profitable pharma titan AbbVie’s (NYSE: ABBV) $228 billion. Viatris owns the rights to manufacture money-printing drugs like Lipitor, Lyrica, Xanax, Viagra, and Zoloft, all of which are available as generics. Because the demand for generic drugs is largely predictable, it hopes to pay out an ever-increasing dividend to its shareholders using stable cash flows.
